Clinical trials
Advanced Solid Cancer clinical trials
Below are recruiting advanced solid cancer clinical trials, each written for real people, not researchers. We’re tracking 1,302 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07650240RecruitingPhase 2
PSMA Therapy and Hormone Treatment for Early-Stage Prostate Cancer Spread
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
Rochester, MinnesotaAges 18 years+ - NCT06934538RecruitingPhase 1/Phase 2
Immunotherapy trial for advanced colorectal cancer
This trial tests a new immunotherapy drug (STC-1010) for people with colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the drug can shrink tumors or slow the disease.
Baltimore, MarylandAges 18–75 - NCT07225309Recruiting
Meaning-Centered Therapy for Mexican Adults with Advanced Cancer
This study tests a therapy program called Meaning-Centered Therapy designed to help adults in Mexico with advanced cancer find meaning and improve their well-being. It involves sessions delivered by trained providers at the National Cancer Institute in Mexico (INCan).
New York, New YorkAges 18 years+ - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT04412616RecruitingPhase 1
Study drug for advanced EGFR-positive solid tumors
This early-phase trial tests a new drug (ZZ06) in adults with advanced solid cancers that have an EGFR “positive” tumor test result. It’s for people whose cancer has grown despite standard treatment or who don’t have a standard option.
Los Angeles, CaliforniaAges 18 years+ - NCT04945330Recruiting
Study for NTRK fusion cancers taking larotrectinib
This trial is for people with advanced or returning solid tumors that have specific gene changes called NTRK gene fusions. It looks at patients who are already being treated with larotrectinib as part of normal care, to understand this treatment in real life.
Multiple LocationsAges Any age - NCT04389281RecruitingPhase 1
X-ray light-activated therapy for hard-to-treat skin tumors
This early-phase study tests an X-ray–activated medicine that is delivered directly into selected tumors to help control cancer that has not responded to standard treatments. If the injected area can be treated safely, it may shrink or slow the tumor and improve local control.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07348211RecruitingPhase 1
Study of SIM0610 for advanced solid tumors
This trial tests a new drug called SIM0610 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT05518253RecruitingPhase 1
CAR-T treatment for CD70-positive advanced solid tumors
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
Hangzhou, ZhejiangAges 18 years+ - NCT06075524Recruiting
How PD-1 therapy affects immune cells in advanced cancers
This study looks at how your immune system responds to PD-1/PD-L1 immunotherapy (drugs like Keytruda or Opdivo) for advanced melanoma, lung cancer, and similar cancers. It involves regular blood tests to track your immune cells, which may help doctors understand why these treatments work for some people better than others.
Rochester, MinnesotaAges 18 years+ - NCT06225856RecruitingPhase 1
YY201 for advanced solid tumors and blood cancers
This trial tests a new drug, YY201, that targets a protein called STAT3, which may help certain advanced solid tumors and blood cancers. It is for people who have tried standard treatments without success.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06015048RecruitingPhase 1/Phase 2
SHR-A1811 plus other therapies for advanced HER2+ tumors
This trial tests a new medicine called SHR-A1811 combined with other cancer treatments for advanced solid tumors that have HER2 protein or HER2 mutations. It may help people whose cancer has not responded to other treatments.
Hefei, AnhuiAges 18–75 - NCT07321574RecruitingPhase 2
Testing ABP1011T for advanced solid tumors
This trial tests an experimental pill called ABP1011T for people with advanced solid tumors that are no longer responding to standard treatments. It is especially focused on small cell lung cancer and other cancers that might be sensitive to this drug. The goal is to see if the pill can shrink tumors or slow their growth.
Luoyang, HenanAges 18–75 - NCT07285395RecruitingPhase 1
Study of AT1019 with radiation and immunotherapy for advanced solid tumors
This trial tests a new drug called AT1019 given together with targeted radiation (SBRT) and an immunotherapy drug for people with advanced solid tumors that are already being treated with immunotherapy. It aims to see if this combination can shrink or control tumors better.
Xuzhou, JiangsuAges 18 years+ - NCT07136779RecruitingPhase 1/Phase 2
Study of VBC101 for advanced solid tumors
This trial tests a new drug called VBC101 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if VBC101 is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT06840821RecruitingPhase 1/Phase 2
Testing MB0151 for cancers with somatostatin receptors
This trial tests a new drug, MB0151, for adults with advanced solid tumors that have somatostatin receptors and have not responded to standard treatments. It aims to see if MB0151 is safe and can shrink tumors.
Jinan, ShandongAges 18 years+ - NCT06224855RecruitingPhase 1
Study of DXC006 for advanced solid tumors and blood cancers
This trial tests a new drug, DXC006, for people with advanced solid tumors or blood cancers like multiple myeloma and neuroblastoma that have not responded to standard treatments. The goal is to see if it is safe and effective.
Hefei, AnhuiAges 18 years+ - NCT05423977Enrolling by invitationPhase 1
Testing ZV0203 for HER2-positive advanced solid tumors
This Phase 1 study tests ZV0203, a new investigational treatment, in people with HER2-positive advanced or metastatic solid tumors that cannot be removed and have not responded to standard treatment. The goal is to find a safe dose and see how the disease responds.
Zigong, ShandongAges 18 years+ - NCT05276310RecruitingPhase 1
Study of IMC-002 in advanced cancer
This study tests a new drug called IMC-002 in people with advanced cancer that has not responded to standard treatment. It aims to see if the drug is safe and effective, and may be given alone or with other treatments depending on the cancer type.
Goyang-siAges 19 years+ - NCT05067283RecruitingPhase 1
Study of Calderasib for KRAS G12C advanced cancers
This trial tests a new drug, Calderasib, for people with advanced solid tumors that have a specific mutation called KRAS G12C. It may help if your cancer has not responded to previous treatments or if you have certain types of lung or colorectal cancer.
Tampa, FloridaAges 18 years+ - NCT06901531RecruitingPhase 3
Study of zolbetuximab with pembrolizumab and chemo for gastric cancer
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
Birmingham, AlabamaAges 18 years+ - NCT06682117Recruiting
A study of a personalized vaccine for advanced solid tumors
This trial tests a personalized vaccine made from your own cells to help your immune system attack tumor-specific targets. It may be an option if standard treatments have stopped working or caused side effects you can't tolerate.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT03093116RecruitingPhase 1/Phase 2
Repotrectinib for ALK, ROS1, or NTRK tumor gene changes
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
Duarte, CaliforniaAges 12 years+ - NCT07678593RecruitingPhase 1/Phase 2
Study of a new drug combined with standard therapy for RAS-mutated cancers
This study tests a new drug (GFH276) combined with either cetuximab or chemotherapy for people with advanced solid tumors or pancreatic cancer that have a specific genetic change (RAS mutation). The goal is to see if this combination can shrink tumors or slow their growth.
Concord, New South WalesAges 18 years+
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid cancer?
- Yes. Clin2 currently lists 1,302 recruiting advanced solid cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.